Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
AOD-9604 Pharmacokinetics & Metabolism Absorption & Distribution AOD-9604 exhibits unusual pharmacokinetic properties for a peptide, demonstrating activity via multiple administration routes in preclinical models: Oral bioavailability confirmed in pig and rodent studies, an uncommon characteristic for peptide compounds Rapid systemic distribution following intraperitoneal administration in mice (15-30 minutes) Following IV administration in pigs, AOD-9604 and degradation fragments appeared rapidly in plasma Oral administration showed slower kinetics but similar degradation product profiles Distribution studies using radiolabeled peptide (C-14-AOD9604) in rats revealed: Elevated concentrations in pineal body and thyroid tissues Distribution to all non-CNS tissues examined Minimal penetration of blood-brain barrier Tissue-specific accumulation patterns suggesting potential targeting mechanisms Metabolism & Elimination The metabolic fate of AOD-9604 involves rapid degradation through sequential N-terminal amino acid removal,: Plasma half-life of approximately 3 minutes following IV administration in pigs (compared to 21 minutes for full-length growth hormone) Sequential amino-terminal truncation represents the primary degradation pathway Principal metabolites identified in vivo include -2 amino acid and -3 amino acid fragments These truncated fragments retain some reduced in vitro anti-lipogenic activity A significant pharmacokinetic paradox exists: despite rapid plasma clearance (peptide undetectable at 56 minutes in spiked plasma studies), biological effects on body weight and fat metabolism persist for hours to days
Route of Administration How a peptide is delivered dramatically affects how long it stays in the body: Subcutaneous injection : slower absorption, longer duration Intramuscular injection : faster peak concentration, moderate duration Oral and intranasal peptides : often rapidly broken down, requiring protective technologies or higher doses For example, oral BPC-157 may work primarily through gut-localized pathways, while injectable versions may provide broader systemic benefits
This philosophy extends across our entire catalog, from foundational research compounds like BPC-157 to more complex formulations like our Wolverine Peptide Stack
Because it is so central to how cells manage oxidative stress, it has been studied widely
